Investigators at the
University of California, San Francisco are interested in
finding out the effect exenatide and/or rosiglitazone therapy on
insulin resitance.
Who can sign up for this study?
To
be eligible, you must have type 2 Diabetes, be between the ages
of 18 and 75 years old, have an
HbA1c of
7.0% to 10.0%, and be taking
Glucophageâ
(Metformin).
What will happen in this study?
If you
qualify, you will take either exenatide, rosiglitazone, or both
for 20 weeks. During this time, you will come to UCSF for 10
visits to be examined, interviewed, and undergo some tests to
determine your level of insulin resistance before the initiation
of the study drug and after 20 weeks of treatment. The
investigators are interested in finding out the effect of this
drug therapy on insulin resistance.
How long will the study last?
If
you qualify, you will be followed for 20 weeks.
Reimbursement
You will
receive study related medical
exams and lab work, glucose monitor and supplies and
compensation for travel.
If you are interested in this study or have any questions,
please contact
the
Study Coordinator, Christine Torok, at (415)
353-7940
or
Christine.Torok@ucsf.edu
|
- The Type 1 Diabetes Genetics Consortium
Principal Investigator: Stephen E. Gitelman, M.D.,
Director of the Pediatric Diabetes Program at U.C.S.F.
The Type 1 Diabetes Genetics Consortium is trying to
understand the genetic causes of Type 1 Diabetes. We are looking
for families with two siblings (brothers or sisters) with Type 1
Diabetes. If eligible, the siblings, along with other members of
their immediate family will be asked to have a small amount of
blood drawn and to answer a few questions about their health.
There will be a $25.00 reimbursement for each eligible
participating family member.
To find out more information, contact study coordinators
David Ng at (415) 514-3730 or Kathleen Breen, RN at
(415) 502-8640.
|
- TrialNet Natural History Study of the Development of
Type 1 Diabetes
Principal Investigator: Stephen E. Gitelman, M.D.,
Director of the Pediatric Diabetes Program at U.C.S.F.
The UCSF Pediatric Diabetes Clinical Research Program is
screening relatives of people with type 1 diabetes (T1D) to find
out if these family members are at risk for developing diabetes.
Screening involves a simple blood test for the presence of
diabetes-related autoantibodies that may appear years before T1D
develops. This screening is part of a national research program
called Type 1 Diabetes TrialNet and is being conducted to help
understand more about the development of T1D and to look at ways
to delay or prevent T1D.
First-degree blood relatives (brothers, sisters,
parents, and siblings) who are 1 to 45 years old as well as
second-degree blood relatives (cousins, uncles, aunts,
nieces, nephews, half-siblings) who are 1 to 20 years old may be
screened.
If you learn that you are at risk for developing T1D,
additional tests will be offered to estimate your chances of
developing T1D. You will be closely monitored for early
detection of T1D. Early detection may reduce your chances of
developing complications.
In addition, TrialNet has other studies under development. If
you qualify, you may have an opportunity to be enrolled in a
diabetes prevention study. The goal of prevention studies is to
determine whether new therapies can delay or prevent the onset
of T1D in "at-risk" individuals. If you do develop T1D, and if
you qualify, you may have the opportunity to be enrolled in an
intervention study. The goal of these studies is to preserve
insulin secretion in people with newly diagnosed T1D.
To find out more information, contact study coordinators
David Ng at (415) 514-3730 or Kathleen Breen, RN at
(415) 502-8640.
|
- Improving Metabolic Assessments in Type 1 Diabetes:
Comparing Two Tests to Measure Insulin Secretion
Principal Investigator: Stephen E. Gitelman, M.D.,
Director of the Pediatric Diabetes Program at U.C.S.F.
The UCSF Pediatric Diabetes Clinical Research Program is
conducting a study to compare two tests that measure how much
insulin is being made by the body. The purpose of the study is
to determine which test will be better to use in future studies
that will be trying to determine if certain medications will
preserve the insulin producing function of the pancreas.
We are looking for volunteers between 8 and 35 years old who
have been diagnosed with type 1 diabetes within the past 3
years. There will be four study visits. Each visit will involve
the placement of an IV line (small plastic tube in a vein in
your arm) and several small blood draws through the IV. Two
visits will take about 30 minutes each and two visits will take
about 21/2 hours each. Subjects will be reimbursed $200.00 for
completing the study, or $50.00 per completed test.
To find out more information, contact study coordinators
David Ng at (415) 514-3730 or Kathleen Breen, RN at
(415) 502-8640.
|
- Optiscan:
volunteers needed for glucose monitor study. If
interested, contact:
Peggy Magarian (510) 865-1195 X 147.
|
- Medtronic is conducting
a research study to evaluate the effectiveness of Gastric
Electrical Stimulation to treat symptoms associated with
gastroparesis in diabetes patients. For more information or
to refer a patient contact:
(CPMC) Dr. William Snape,
Gastroenterologist
2340 Clay, #230
San Francisco, CA
94115
(415) 600-1138
wsnape@aol.com
Hildie Golding,
Research Coordinator
2200 Webster, #413
San Francisco, CA
94115
(415)600-1155
goldinH@sutterhealth.org
(Medtronic) Naomi Tatarek, RN,
Clinical Study Manager
(763)514-9685
Cindy Olson,
Sr. Global Product Manager
(763) 514-9525
Information about the gastric
stimulator can be found at
www.enterratherapy.com.
|
|
RESEARCH
|
|
